TY - JOUR
T1 - Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
AU - Samples, Laura
AU - Sadrzadeh, Hossein
AU - Frigault, Matthew J.
AU - Jacobson, Caron A.
AU - Hamadani, Mehdi
AU - Gurumurthi, Ashwath
AU - Strati, Paolo
AU - Shouval, Roni
AU - Noy, Ariela
AU - Riedell, Peter A.
AU - Dahiya, Saurabh
AU - Maloney, David G.
AU - Till, Brian G.
AU - Hirayama, Alexandre V.
AU - Gauthier, Jordan
AU - Gopal, Ajay K.
AU - Smith, Stephen D.
AU - Poh, Christina
AU - Lynch, Ryan
AU - Ujjani, Chaitra
AU - Di, Mengyang
AU - Raghunathan, Vikram
AU - Shakib-Azar, Mehrdad
AU - Naresh, Kikkeri N.
AU - Gooley, Ted A.
AU - Yared, Jean
AU - Jain, Michael D.
AU - Locke, Frederick L.
AU - Leslie, Lori Ann
AU - Epperla, Narendranath
AU - Ghosh, Monalisa
AU - Skarbnik, Alan
AU - Hill, Brian T.
AU - Kamdar, Manali K.
AU - Ortiz-Maldonado, Valentin
AU - Martinez-Cibrian, Nuria
AU - Shune, Leyla
AU - Shadman, Mazyar
N1 - Publisher Copyright:
© 2025 American Society of Hematology
PY - 2025/6/5
Y1 - 2025/6/5
N2 - Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T cells after a median of 3 previous therapies (range, 1-6). Patients received axicabtagene ciloleucel (n = 19), lisocabtagene maraleucel (n = 4), tisagenlecleucel (n = 4), or other agents (n = 4). Grade 1 to 2 cytokine release syndrome occurred in 83.9% of patients (grade ≥3, 65%), and grade 1 to 2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 29% of patients (grade ≥3, 19.4%). The 28-day mortality rate was 16.1%, including 1 patient who died from grade 5 ICANS. The overall response rate at 1 month was 58.0% with a complete response (CR) rate of 41.9%; however, the 6-month CR rate was only 19.4%. The median progression-free survival was 2.3 months (95% confidence interval, 1.0-9.0), and the median overall survival was 6.0 months (95% confidence interval, 1.9-11.5). Three patients (9.7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed. In conclusion, CD19 CAR T-cell therapy infrequently delivers long-term disease control in BL. Further investigation is needed to determine the most effective alternative management strategy for these patients.
AB - Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T cells after a median of 3 previous therapies (range, 1-6). Patients received axicabtagene ciloleucel (n = 19), lisocabtagene maraleucel (n = 4), tisagenlecleucel (n = 4), or other agents (n = 4). Grade 1 to 2 cytokine release syndrome occurred in 83.9% of patients (grade ≥3, 65%), and grade 1 to 2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 29% of patients (grade ≥3, 19.4%). The 28-day mortality rate was 16.1%, including 1 patient who died from grade 5 ICANS. The overall response rate at 1 month was 58.0% with a complete response (CR) rate of 41.9%; however, the 6-month CR rate was only 19.4%. The median progression-free survival was 2.3 months (95% confidence interval, 1.0-9.0), and the median overall survival was 6.0 months (95% confidence interval, 1.9-11.5). Three patients (9.7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed. In conclusion, CD19 CAR T-cell therapy infrequently delivers long-term disease control in BL. Further investigation is needed to determine the most effective alternative management strategy for these patients.
UR - http://www.scopus.com/inward/record.url?scp=105001231815&partnerID=8YFLogxK
U2 - 10.1182/blood.2024026831
DO - 10.1182/blood.2024026831
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39938007
AN - SCOPUS:105001231815
SN - 0006-4971
VL - 145
SP - 2762
EP - 2767
JO - Blood
JF - Blood
IS - 23
ER -